APPLY TREATMENT TO CLINICAL SYNDROMES
HIV Antiretroviral Pharmacology
Antiretroviral therapy suppresses HIV replication, supports immune recovery, and reduces HIV-associated illness and mortality. Treatment is recommended for all people with HIV and is generally initiated promptly.
Regimen selection incorporates viral resistance, hepatitis B status, kidney function, pregnancy considerations, interactions, tolerability, and the patient’s ability to maintain treatment (Banoub et al., 2026).
Connect Drug Classes to the Viral Life Cycle
Nucleoside and nucleotide reverse transcriptase inhibitors interfere with conversion of viral RNA into DNA. Common agents include tenofovir, emtricitabine, and lamivudine.
Nonnucleoside reverse transcriptase inhibitors act at a different site on reverse transcriptase. Their resistance patterns and interactions differ from those of the nucleoside agents.
Integrase strand transfer inhibitors prevent incorporation of viral DNA into host DNA. Bictegravir and dolutegravir are central to many initial regimens.
Protease inhibitors interfere with processing of viral proteins and formation of mature infectious particles. Other classes act at entry, attachment, fusion, or capsid-related stages and may serve selected treatment or prevention roles.
Combination treatment targets replication while limiting the opportunity for resistance. The number of tablets does not indicate the number of active drugs (Banoub et al., 2026).
Select an Initial Regimen
For many treatment-naive, nonpregnant adults, representative options include bictegravir/tenofovir alafenamide/emtricitabine or dolutegravir with an appropriate tenofovir/emtricitabine or tenofovir/lamivudine backbone.
Dolutegravir/lamivudine is suitable only for selected patients. Relevant resistance and hepatitis B status must be known, and additional eligibility restrictions apply. It should not be treated as a universal rapid-start regimen.
Rapid initiation can proceed before every baseline result returns when a suitable regimen is selected. The regimen must then be reassessed as results become available (Banoub et al., 2026; New York State Department of Health AIDS Institute [NYSDOH AI], 2026).
Complete Baseline Assessment
Obtain HIV RNA, CD4 count, resistance testing, blood counts, renal and hepatic assessment, and hepatitis testing. Additional testing depends on pregnancy potential, tuberculosis risk, sexually transmitted infections, and the planned regimen.
HIV RNA measures viral replication and treatment response. CD4 count reflects immune status and helps determine opportunistic-infection prevention needs.
If abacavir is being considered, HLA-B*5701 testing is required to assess hypersensitivity risk. A negative result does not eliminate all medication risks or make abacavir the preferred option for every patient (Banoub et al., 2026).
Account for Hepatitis B and Organ Function
Tenofovir with emtricitabine or lamivudine provides hepatitis B activity within an HIV regimen. In HIV/HBV coinfection, avoid leaving lamivudine or emtricitabine as the sole HBV-active agent.
Stopping HBV-active therapy can precipitate hepatitis flares. Regimen changes require a plan for continued HBV treatment when indicated.
Tenofovir disoproxil fumarate has important renal and bone considerations. Tenofovir alafenamide generally produces lower systemic tenofovir exposure, but formulation-specific renal restrictions and metabolic considerations still apply (Banoub et al., 2026).
Evaluate Interactions Before Prescribing
Polyvalent cations in antacids and supplements can reduce absorption of oral integrase inhibitors. Separation and food instructions depend on the specific drug and product.
Ritonavir and cobicistat are pharmacokinetic enhancers with substantial interaction potential. Corticosteroids, statins, anticoagulants, sedatives, and other medications may require avoidance or adjustment.
Acid suppression can reduce exposure to selected agents, including oral rilpivirine. Enzyme-inducing drugs can undermine antiviral exposure. Review prescriptions, over-the-counter products, supplements, and intermittent medications before every treatment change (Banoub et al., 2026).
Monitor Response and Access
Assess tolerability and adherence soon after initiation. The NYSDOH AI guideline recommends contact within approximately two weeks and viral load testing within four weeks.
Continue viral load assessment until suppression is established. An isolated detectable result followed by renewed suppression may represent a viral blip. Confirmed HIV RNA of 200 copies/mL or more warrants evaluation of adherence, access, interactions, treatment history, and resistance; a single low-level result should not trigger an unexamined regimen change. Monitor kidney function, liver tests, metabolic effects, and other parameters according to the regimen and patient risks.
When viral load rises, evaluate adherence, access, interactions, absorption, and resistance. Do not presume that a patient has intentionally stopped treatment or add a single drug to a failing regimen without a resistance-informed plan (Banoub et al., 2026; NYSDOH AI, 2026). People who achieve and maintain HIV RNA below 200 copies/mL do not sexually transmit HIV, the evidence base for Undetectable Equals Untransmittable, or U=U.
Distinguish Treatment From Prevention
Pre-exposure prophylaxis is used in people without HIV who may benefit from prevention. Post-exposure prophylaxis is an urgent, time-limited intervention after an eligible exposure. Neither should be substituted for a complete treatment regimen in established HIV infection.
Long-acting options can reduce daily pill burden for selected patients but create different adherence requirements, including injection scheduling and management of missed doses. Eligibility and resistance considerations remain essential (Banoub et al., 2026). PrEP options include daily oral and long-acting injectable regimens for eligible people after exclusion of HIV and medication-specific baseline assessment. PEP is a medical urgency: begin as soon as possible and no later than 72 hours after a qualifying exposure, and continue the recommended regimen for 28 days.
Related YourDNP Resources
Content last reviewed:
References
Centers for Disease Control and Prevention. (2025, February 10). Clinical guidance for PEP. https://www.cdc.gov/hivnexus/hcp/pep/
Centers for Disease Control and Prevention. (2026, April 30). Clinical guidance for PrEP. https://www.cdc.gov/hivnexus/hcp/prep/
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2026). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv
Banoub, M. F., Bailey, J. L., & Bernice, F. (2026). Human immunodeficiency virus infection. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed.). McGraw Hill.
New York State Department of Health AIDS Institute. (2026, January 29). Selecting an initial ART regimen. Clinical Guidelines Program. https://www.hivguidelines.org/guideline/hiv-initial-art/